Skip to content

Expanded Indications in the MED-EL Pediatric Cochlear Implant Population

Expanded Indications in the MED-EL Pediatric Cochlear Implant Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03900897
Enrollment
247
Registered
2019-04-03
Start date
2019-06-17
Completion date
2023-11-01
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Sensorineural

Brief summary

The purpose of this investigation is to demonstrate the safety and effectiveness of MED-EL cochlear implants in children 7 months to 5 years, 11 months of age who fall outside the current FDA-approved candidacy criteria and, yet, continue to demonstrate insufficient functional access to sound with appropriately fit hearing aids and aural habilitation.

Interventions

DEVICEMED-EL SYNCHRONY PIN Cochlear Implant

Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.

OTHERCochlear Implant

Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.

Sponsors

Med-El Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicenter, open-label, non-randomized, repeated-measures design with two study arms as follows. Prospective: interventional study arm with prospective enrollment and treatment through one year of implant use. Retrospective: observational study arm with retrospective protocol for systematic chart review of patients with at least one year of implant use.

Eligibility

Sex/Gender
ALL
Age
7 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* Children 7 months to 5 years 11 months of age at the time of implantation * Bilateral, severe to profound sensorineural hearing loss (SNHL) in the high frequencies and * For subjects implanted under 12 months of age: bilateral, severe to profound SNHL in the low frequencies * For subjects implanted at 12 months to 5 years 11 months of age: bilateral, mild to profound sensorineural hearing loss in the low frequencies * Insufficient functional access to sound with appropriately fit amplification and aural habilitation * Objective measures consistent with repeatable unaided audiometric thresholds for subjects under 12 months of age * Radiologic evidence of potential for full insertion with one of the included electrode arrays * Ability to undergo general anesthesia * At least one parent/guardian who is fluent in one of the available languages of the LEAQ * Parental commitment to study parameters

Exclusion criteria

* Magnetic Resonance Imaging (MRI) evidence of cochlear nerve deficiency * Active middle ear infection * Permanent conductive hearing loss * Treatable mixed hearing loss * Current or history of meningitis * Common cavity * Skin or scalp condition precluding use of external audio processor * Suspected cognitive impairment, organic brain dysfunction, or syndromic etiology that may affect performance * ASA (American Society of Anesthesiologists) Class 3 or higher in subjects under 12 months of age * History of prior use of a hearing implant * Unrealistic parental/patient expectations * Child is not able to complete speech perception testing in English

Design outcomes

Primary

MeasureTime frameDescription
Total Score on LittlEARS Auditory Questionnaire (LEAQ)Up to 12 Months Post-ActivationClinical success defined as a Total Score of 25 or more on the LittLEARS Auditory Questionnaire (LEAQ). Total Score ranges from zero to 35, with higher scores indicating development of increasingly complex listening skills.
Percent correct on Multisyllabic Lexical Neighborhood Test (MLNT)/Lexical Neighborhood Test (LNT)Up to 12 Months Post-ActivationClinical success defined as an improvement of 10 percentage points or more on MLNT/LNT.
Number and proportion of subjects experiencing device- and/or procedure-related adverse events.Up to 12 Months Post-ActivationAdverse events will be collected and reported throughout the duration of the study.

Secondary

MeasureTime frameDescription
Total Score on LittlEARS Auditory Questionnaire (LEAQ)Up to 12 Months Post-ActivationChange from baseline in Total Score on the LittlEARS Auditory Questionnaire (LEAQ). Total Score ranges from zero to 35, with higher scores indicating development of increasingly complex listening skills. The LittlEARS Auditory Questionnaire is intended for young children with zero to 24 months of listening experience.
Total Score on Auditory Skills Checklist (ASC)Up to 12 Months Post-ActivationChange from baseline in Total Score on the Auditory Skills Checklist (ASC). Total Score ranges from zero to 70, with higher scores indicating development of increasingly complex listening skills. The Auditory Skills Checklist is intended for children from zero to 18 years of age.
Speech recognition testing in the implanted ear(s)Up to 12 Month Post-ActivationPercent change from baseline scores on speech recognition testing with words in quiet and sentences in quiet and noise.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026